A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone Versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

Study Status

Open to Enrollment

Study Description

This clinical trial is for men and women with multiple myeloma who have had 1 to 3 prior therapies for myeloma and who have progressed, or relapsed, following one of their treatments. 

The purpose of the study is to compare the effectiveness of the combination of the experimental drug carfilzomib and dexamethasone, versus the combination of bortezomib (also called Velcade) and dexamethasone in treating relapsed multiple myeloma. 

Carfilzomib and bortezomib are both a type of drug called a proteasome inhibitor. They work by preventing the breakdown of abnormal proteins in cells, causing the cells the die. Cancer cells are more sensitive to these effects than normal cells. Bortezomib is FDA-approved to treat multiple myeloma. Dexamethasone is a steroid and is also FDA-approved. 

Study participants will be randomly assigned to one of two study arms: 

  • Arm 1, Carfilzomib + Dexamethasone: Each dosing cycle is 28 days; participants will receive  carfilzomib via infusion 2 times per week for 3 out of 4 weeks of each cycle, and dexamethasone 2 times per week for 4 weeks of each cycle 
  • Arm 2, Bortezomib (Velcade) + Dexamethasone: Each dosing cycle is 21 days; participants will receive bortezomib via injection 2 times per week for 2 out of 3 weeks of each cycle, and dexamethasone 4 times per week for 2 out of 3 weeks of each cycle

Participants may continue to receive the study therapies as long as they continue to respond to and are able to tolerate the treatment. 

Follow the Myeloma Center online

                          Website: http://myelomacenter.org 

                          Blog: http://myelomacenterblog.com 

                          Facebook: Click here to visit the Myloma Facebook Page 

Disease Status and/or Stage

Relapsed Multiple Myeloma


Onyx Pharmaceuticals

Key Eligibility

  • Men and women age 18 and older
  • Diagnosed with multiple myeloma
  • Have received at least 1 and no more than 3 treatment regimens or lines of therapy for multiple myeloma
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Ruben Niesvizky, MD


Protocol ID


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page